Surrozen(NASDAQ) SRZN

Surrozen makes medicines to help the body fix damaged tissues. It creates eye treatments for people suffering from vision loss. These drugs aim to repair tissue and improve patient sight.

Fixing the Body From Within

• SZN-413: Partnered bi-specific antibody targeting retinal vascular integrity through specific biological pathways; accounted for 100% of revenue in Q1 2026.
• SZN-8141: Experimental therapy for retinal diseases that combines vessel growth control and tissue repair signaling.
• SZN-8143: Multi-action antibody candidate designed to reduce eye inflammation and restore tissue function.
• Research Programs: Laboratory-stage efforts focused on healing corneal injuries and protecting eye nerves.

Strategic Deals and Lab Milestones

• Partnered with Boehringer Ingelheim International GmbH in October 2022 to develop and commercialize antibody-based eye treatments.
• Established a $175 million private financing agreement in March 2025 to support clinical operations through a two-stage investment structure.
• Raised $26.9 million in the first quarter of 2026 through an at-the-market equity sales program with TD Cowen.
• Achieved a $5 million research milestone in March 2026 following successful toxicology studies for its lead partnered antibody program.

What Makes Surrozen Different

Surrozen uses proprietary engineering platforms to create antibodies that selectively activate natural tissue-repair pathways within the body. This approach allows the company to target specific organs like the eye while minimizing biological activity in other areas to reduce potential side effects.

A Look at the Books

• Revenue reached $5 million in Q1 2026, up 408.6% from $983,000 in Q1 2025.
• Net loss deepened to $127.5 million in Q1 2026, compared to a $27 million loss in Q1 2025.
• Operating loss worsened to $10.5 million in Q1 2026, representing a 9.5% increase year-over-year.
• Cash and cash equivalents totaled $106.9 million as of March 31, 2026.

The Final Word

Surrozen has transitioned from broad biological research to a concentrated focus on repairing vision through tissue-selective antibody engineering. Its long-term trajectory depends on advancing its current pipeline into clinical testing while managing high non-cash expenses related to its financing structures.